<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01479348</url>
  </required_header>
  <id_info>
    <org_study_id>120014</org_study_id>
    <secondary_id>12-C-0014</secondary_id>
    <nct_id>NCT01479348</nct_id>
  </id_info>
  <brief_title>Imaging Study for FdCyd and THU Cancer Treatment</brief_title>
  <official_title>Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - The drugs FdCyd (also called 5-fluoro-2'-deoxycytidine) and THU (also called
      tetrahydrouridine) are being used in a cancer treatment study. Not a lot is known about how
      FdCyd works in the body. Researchers want to look at a modified form of FdCyd using imaging
      studies to see how the drug reacts with the cancer. This study is not a treatment study. It
      is open only to people who are already on the FdCyd and THU cancer treatment study.

      Objectives:

      - To study how FdCyd affects advanced cancer cells.

      Eligibility:

      - Participants in National Cancer Institute study 09-C-0214.

      Design:

        -  Participants will have two imaging studies, one before starting FdCyd and THU treatment
           and one after starting treatment.

        -  Participants will have the modified FdCyd, known as F-18 FdCyd, with a dose of THU. The
           doses will be followed by two imaging study scans and frequent blood samples.

        -  This procedure will be repeated at a later date, during the FdCyd and THU treatment
           period.

        -  Treatment will not be provided as part of this study. This is an imaging study protocol
           only....
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      - In pre-clinical models, 5-fluoro-2-deoxycytidine (FdCyd), administered along with

      tetrahydrouridine (THU; an inhibitor of cytidine/deoxycytidine deaminase), has shown superior
      anti-tumor activity as compared with 5-fluorouracil.

      - FdCyd can be phosphorylated to 5-fluoro-2-deoxycytidylate (FdCMP) by deoxycytidine

      kinase and the nucleotide deaminated to FdUMP by deoxycytidylate (dCMP) deaminase.

      The activity of dCMP deaminase is reported to be higher in human malignancies than in normal
      tissues, which may result in selective cytotoxicity.

        -  FdCyd is an inhibitor of deoxyribonucleic acid (DNA) methyltransferase and DNA
           methylation, resulting in reexpression of genes silenced by DNA hypermethylation. It is
           being evaluated in a phase II multihistology clinical trial at the Developmental
           Therapeutics Clinic, National Cancer Institute (NCI), Clinical Center, National
           Institutes of Health (NIH).

        -  While FdCyd + THU has shown preliminary evidence of activity in early phase trials not
           all patients show clinical response. The establishment of a radiolabeled form to image
           the biodistribution in vivo at baseline and during therapy may provide insight into the
           distribution of the therapeutic drug.

        -  The first step in the development of such an in vivo marker is to determine the

      biodistribution and safety of the radiolabeled form.

      OBJECTIVES:

        -  Determine the safety of [F-18]-5-fluoro-2'-deoxycytidine (FdCyd) administered
           intravenously with administration of tetrahydrouridine (THU).

        -  Estimate the radiation dosimetry of [F-18]-FdCyd in humans.

      ELIGIBILITY:

        -  Only patients enrolled in NCI Phase II Study evaluating FdCyd with THU (NCI Protocol #
           09-C-0214 (CTEP# 8351) or NCI Protocol #12-C-0066 (CTEP# 9127)) at the NIH Clinical
           Center will be eligible to participate in this study).

        -  Patients must have a target lesion greater than or equal to 10mm

        -  May not be pregnant or lactating; must be less than or equal to 350 lbs; and may not
           have known allergy to FdCyd or contraindications to positron emission tomography
           (PET)/computed tomography (CT) imaging.

      DESIGN:

        -  There are two arms to this study

        -  The first arm will be patients enrolling in the therapeutic Phase II 5-FdCyd/THU study
           (NCI Protocol # 09-C-0214 (CTEP# 8351) in the NCI Developmental Therapeutics Clinic

        -  The second arm will be patients enrolling in the Phase I 5-FdCyd/THU study (NCI Protocol
           #12-C-0066 (CTEP# 9127)) in the NCI Developmental Therapeutics Clinic.

        -  Patients will undergo an initial [F-18]-FdCyd + THU PET/CT imaging prior to therapeutic
           dosing on study NCI Protocol # 09-C-0214 (CTEP# 8351) or NCI Protocol #12-C-0066 (CTEP#
           9127). Repeat imaging will be performed while the patient is receiving FdCyd + THU
           therapy under the parent therapeutic protocol. This imaging must be completed 2-5 days
           after cycle start and at least 2 hours after a dose. Upon completion of repeat imaging,
           patients will be taken off this imaging study 24 hours after the last imaging session.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow, insufficient accrual.
  </why_stopped>
  <start_date type="Actual">November 1, 2011</start_date>
  <completion_date type="Actual">January 11, 2019</completion_date>
  <primary_completion_date type="Actual">August 4, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and Severity of Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0</measure>
    <time_frame>Within 5 days after interventions</time_frame>
    <description>[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiation Dosimetry Estimates of 5-fluoro-2'-Deoxycytidine (FdCyd) in Humans</measure>
    <time_frame>1 year</time_frame>
    <description>Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor to Background Ratios (TBRs) of Target Lesions at 4 Time Points After Injection</measure>
    <time_frame>9 minutes, 32 minutes, 56 minutes and 2 hours after injection</time_frame>
    <description>Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious and Non-Serious Adverse Events</measure>
    <time_frame>Date treatment consent signed to date off study, approximately 20 months and 12 days.</time_frame>
    <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Lung Neoplasms</condition>
  <condition>Urinary Bladder Neoplasms</condition>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>1/Intravenous (IV) Tetrahydrouridine (THU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2/Oral Tetrahydrouridine (THU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[F-18]-5-FLUORO-2'-DEOXYCYTIDINE</intervention_name>
    <description>18FdCyd radiotracer</description>
    <arm_group_label>1/Intravenous (IV) Tetrahydrouridine (THU)</arm_group_label>
    <arm_group_label>2/Oral Tetrahydrouridine (THU)</arm_group_label>
    <other_name>18FdCyd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrahydrouridine intravenous (IV)</intervention_name>
    <description>Total dose of THU = 350 mg/m^2, IV</description>
    <arm_group_label>1/Intravenous (IV) Tetrahydrouridine (THU)</arm_group_label>
    <arm_group_label>2/Oral Tetrahydrouridine (THU)</arm_group_label>
    <other_name>THU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrahydrouridine (oral)</intervention_name>
    <description>Total dose of THU is 3000 mg, oral</description>
    <arm_group_label>1/Intravenous (IV) Tetrahydrouridine (THU)</arm_group_label>
    <arm_group_label>2/Oral Tetrahydrouridine (THU)</arm_group_label>
    <other_name>THU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Positron emission tomography (PET)/Computed tomography (CT)</intervention_name>
    <description>One prior CT and 3 sequential whole body PET</description>
    <arm_group_label>1/Intravenous (IV) Tetrahydrouridine (THU)</arm_group_label>
    <arm_group_label>2/Oral Tetrahydrouridine (THU)</arm_group_label>
    <other_name>PET scan/CT scan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Enrolled in the National Institutes of Health (NIH) Phase II Clinical protocol
             evaluating 5-fluro-2'-deoxycytidine (FdCyd) with Tetrahydrouridine (THU) (09-C-0214)
             with target lesion measured as greater than or equal to 10mm with spiral computed
             tomography (CT) scan.

          -  Written, voluntary, informed consent of the patient must be obtained in compliance
             with institutional, state and federal guidelines

          -  For females: Negative serum pregnancy test OR post-menopausal for at least 2 years OR
             patient has had a hysterectomy

        EXCLUSION CRITERIA:

          -  Participants with severe claustrophobia unresponsive to oral anxiolytics

          -  Subjects weighing &gt; 400 lbs (weight limit for scanner table), or unable to fit within
             the imaging gantry

          -  Known allergy to FdCyd

          -  The subject is unable to lie still for 75 minutes

          -  5 Pregnant or lactating women. Pregnant women are excluded from this study because the
             effects of 18F-FdCyd in pregnancy are not known. Because there is an unknown but
             potential risk for adverse events in nursing infants secondary to administration of
             18F-FdCyd in the mother, breastfeeding should be discontinued if the mother receives
             18F-FdCyd

          -  Participants with any co-existing medical or psychiatric condition that is likely to
             interfere with study procedures and/or results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen A Kurdziel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Carter SK. Editorial: Large-bowel cancer-The current status of treatment. J Natl Cancer Inst. 1976 Jan;56(1):3-10.</citation>
    <PMID>1255749</PMID>
  </reference>
  <reference>
    <citation>Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, Carr B, Bertrand M, Goldberg D, Blayney D, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol. 1990 Mar;8(3):491-501.</citation>
    <PMID>2407810</PMID>
  </reference>
  <reference>
    <citation>HARTMANN JR, ORIGENES ML Jr, MURPHY ML, SITARZ A, ERLANDSON M. EFFECTS OF 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) AND 5-FLUOROURACIL (NSC-19893) ON CHILDHOOD LEUKEMIA. Cancer Chemother Rep. 1964 Jan;34:51-4.</citation>
    <PMID>14116219</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 22, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2011</study_first_posted>
  <results_first_submitted>April 27, 2020</results_first_submitted>
  <results_first_submitted_qc>May 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 22, 2020</results_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>Peter Choyke, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Imaging</keyword>
  <keyword>Radiopharmaceutical</keyword>
  <keyword>Safety</keyword>
  <keyword>Dosimetry</keyword>
  <keyword>Drug Distribution</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetrahydrouridine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT01479348/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: IV FdCyd + THU</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT01479348/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Oral FdCyd + THU</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT01479348/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No participants were enrolled in the 2/Oral Tetrahydrouridine (THU) Group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1/Intravenous (IV) Tetrahydrouridine (THU)</title>
          <description>[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
[F-18]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer
Tetrahydrouridine intravenous (IV): Total dose of THU = 350 mg/m^2, IV
Tetrahydrouridine (oral): Total dose of THU is 3000 mg, oral
Positron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET</description>
        </group>
        <group group_id="P2">
          <title>2/Oral Tetrahydrouridine (THU)</title>
          <description>[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
[F-18]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer
Tetrahydrouridine intravenous (IV): Total dose of THU = 350 mg/m^2, IV
Tetrahydrouridine (oral): Total dose of THU is 3000 mg, oral
Positron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1/Intravenous (IV) Tetrahydrouridine (THU)</title>
          <description>[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
[F-18]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer
Tetrahydrouridine intravenous (IV): Total dose of Tetrahydrouridine (THU) = 350 mg/m^2, IV
Tetrahydrouridine (oral): Total dose of THU is 3000 mg, oral
Positron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.46" spread="15.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Tumor Types</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Head &amp; Neck Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Small Cell Lung Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatocellular Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency and Severity of Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0</title>
        <description>[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event.</description>
        <time_frame>Within 5 days after interventions</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1/Intravenous (IV) Tetrahydrouridine (THU)</title>
            <description>[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
[F-18]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer
Tetrahydrouridine intravenous (IV): Total dose of Tetrahydrouridine (THU) = 350 mg/m^2, IV
Tetrahydrouridine (oral): Total dose of THU is 3000 mg, oral
Positron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Severity of Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0</title>
          <description>[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, Grade 2 Hypoalbuminemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, Grade 3 Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Radiation Dosimetry Estimates of 5-fluoro-2'-Deoxycytidine (FdCyd) in Humans</title>
        <description>Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1/Intravenous (IV) Tetrahydrouridine (THU)</title>
            <description>[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
[F-18]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer
Tetrahydrouridine intravenous (IV): Total dose of Tetrahydrouridine (THU) = 350 mg/m^2, IV
Tetrahydrouridine (oral): Total dose of THU is 3000 mg, oral
Positron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET</description>
          </group>
        </group_list>
        <measure>
          <title>Radiation Dosimetry Estimates of 5-fluoro-2'-Deoxycytidine (FdCyd) in Humans</title>
          <description>Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data.</description>
          <units>mSv/MBq</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adrenals</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.17" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breasts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gallbladder wall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.05" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower large intestine wall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="7.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small intestine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="4.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach wall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper large intestine wall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="6.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart wall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidneys</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.02" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lungs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="7.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ovaries</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteogenic cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.65" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spleen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Testes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thymus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.23" spread="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary bladder wall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.96" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uterus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor to Background Ratios (TBRs) of Target Lesions at 4 Time Points After Injection</title>
        <description>Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection.</description>
        <time_frame>9 minutes, 32 minutes, 56 minutes and 2 hours after injection</time_frame>
        <population>One participant contributed to data in each row.</population>
        <group_list>
          <group group_id="O1">
            <title>1/Intravenous (IV) Tetrahydrouridine (THU)</title>
            <description>[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
[F-18]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer
Tetrahydrouridine intravenous (IV): Total dose of Tetrahydrouridine (THU) = 350 mg/m^2, IV
Tetrahydrouridine (oral): Total dose of THU is 3000 mg, oral
Positron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor to Background Ratios (TBRs) of Target Lesions at 4 Time Points After Injection</title>
          <description>Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection.</description>
          <population>One participant contributed to data in each row.</population>
          <units>TBR ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pt 1 L. Parotid adenosquam. cell ca at 9 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 1 L. Parotid adenosquam. cell ca at 32 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 1 L. Parotid adenosquam. cell ca at 56 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 1 L. Parotid adenosquam. cell ca at 2 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 3 Non-small Cell Lung Ca at 9 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 3 Non-small Cell Lung Ca at 32 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 3 Non-small Cell Lung Ca at 56 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 3 Non-small Cell Lung Ca at 2 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 4 Non-small Cell Lung Ca at 9 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 4 Non-small Cell Lung Ca at 32 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 4 Non-small Cell Lung Ca at 56 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 4 Non-small Cell Lung Ca at 2 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 5 Hepatocellular Ca at 9 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Activity within the tumor was not clearly discernable from remainder of liver parenchyma, thus TBRs are not included for Pt. 5 because of concern about reporting misleading values in setting of high background/surrounding liver uptake.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 5 Hepatocellular Ca at 32 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Activity within the tumor was not clearly discernable from remainder of liver parenchyma, thus TBRs are not included for Pt. 5 because of concern about reporting misleading values in setting of high background/surrounding liver uptake.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 5 Hepatocellular Ca at 56 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Activity within the tumor was not clearly discernable from remainder of liver parenchyma, thus TBRs are not included for Pt. 5 because of concern about reporting misleading values in setting of high background/surrounding liver uptake.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pt 5 Hepatocellular Ca at 2 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Activity within the tumor was not clearly discernable from remainder of liver parenchyma, thus TBRs are not included for Pt. 5 because of concern about reporting misleading values in setting of high background/surrounding liver uptake.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
        <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Date treatment consent signed to date off study, approximately 20 months and 12 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1/Intravenous (IV) Tetrahydrouridine (THU)</title>
            <description>[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
[F-18]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer
Tetrahydrouridine intravenous (IV): Total dose of Tetrahydrouridine (THU) = 350 mg/m^2, IV
Tetrahydrouridine (oral): Total dose of THU is 3000 mg, oral
Positron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
          <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, approximately 20 months and 12 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1/Intravenous (IV) Tetrahydrouridine (THU)</title>
          <description>[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
[F-18]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer
Tetrahydrouridine intravenous (IV): Total dose of Tetrahydrouridine (THU) = 350 mg/m^2, IV
Tetrahydrouridine (oral): Total dose of THU is 3000 mg, oral
Positron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Karen Kurdziel</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>804-897-1207</phone>
      <email>kurdziek@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

